Influenza surveillance with rapid diagnostic tests.

1. De Meirleir K, Suhadolnik RJ, Lebleu B, Englebienne P. Antiviral pathway activation in chronic fatigue syndrome and acute infection [letter]. Clin Infect Dis 2002; 34:1420–1 (in this issue). 2. Gow JW, Simpson K, Behan PO, Chaudhuri A, McKay IC, Behan WMH. Antiviral pathway activation in patients with chronic fatigue syndrome and acute infection. Clin Infect Dis 2001; 33:2080–1. 3. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121: 953–9. 4. De Meirleir K, Bisbal C, Campine I, et al. A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. Am J Med 2000; 108:99–105. 5. Suhadolnick RJ, Reichenbach NL, Hilzges P, et al. Upregulation of the 2-5A synthetase/ RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis 1994; 18:S96–104. 6. Player MR, Torrence PF. The 2-5A system: modulation of viral and cellular processes through acceleration of protein degradation. Pharmacol Ther 1998; 78:55–113. 7. Suhadolnick RJ, Peterson DL, O’Brien K, et al. Biochemical evidence for a novel low molecular weight 2-5A–dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Research 1997; 17:377–85. 8. Goulding C, et al. Prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C infection” relationship to RT-PCR status and mode of acquisition. Eur J Gastroenterol Hepatol 2001; 13:507–11.